



## PRESS RELEASE

### **SuperSonic Imagine's ShearWave™ Elastography Technology Will be Presented at the International Liver Congress (EASL) 2015 Vienna, Austria**

Aix-en-Provence, France, April 23, 2015 - SuperSonic Imagine (Euronext: SSI, FR0010526814), the highly innovative ultrasound company that pioneered breakthrough ShearWave Elastography technology (SWE™) and UltraFast™ Doppler, announced today that the clinical benefits of its technologies will be presented at the International Liver Congress 2015, the 50<sup>th</sup> Annual Meeting of the European Association for the Study of the Liver (EASL).

Today, more than 40 liver focused publications have demonstrated that SuperSonic Imagine's ShearWave technology is reliable and easy to use. Several additional abstracts regarding the SWE technology will be presented at EASL, including the initial outcomes of a retrospective multicenter study<sup>1</sup> of 1340 patients with chronic liver disease.

SWE is a quick, non-invasive exam that provides color coded maps and quantitative measurements of liver stiffness that help assessing and staging chronic liver disease. As a general rule, liver stiffness increases with the severity of liver fibrosis, making it an important parameter to help physicians determine the stage of fibrosis. This technique could also play a significant role in monitoring antiviral therapies used to address health concerns such as the hepatitis C virus (HCV). SWE may also serve as an adjunct or alternative to traditional diagnostic tools such as liver biopsy or blood tests.

Liver biopsy has traditionally been considered the standard for assessing liver fibrosis severity but this invasive method has major drawbacks, including significant incidence of morbidity, procedure and hospitalization costs, and clinical shortcomings as fibrosis is underestimated in 10-30% of the cases<sup>2-4</sup>. In addition, because of its invasive nature, biopsy is not ideal for repeated follow-up exams.

*"I can reduce my biopsy numbers dramatically during initial fibrosis staging when I use the Aixplorer's real-time, quantitative ShearWave Elastography from SuperSonic Imagine."* said Dr. James Trotter, MD of Baylor Hospital in Dallas, Texas. *"This is especially helpful for my patients who are eligible to receive the new antiviral treatments for HCV. This quick, noninvasive exam improves the overall patient experience."*

*"We are excited to participate in this year's EASL Liver Congress and to have the opportunity to highlight potential benefits of our imaging technology in the assessment of chronic liver disease"*, said Jacques Souquet Ph.D., SuperSonic Imagine's Founder, Executive Vice President and Chief Strategic and Innovation Officer. *"This technology will facilitate patient monitoring by allowing physicians to see the liver image and quantify liver stiffness values in one simple exam."*

The Company will be exhibiting at booth 320E throughout EASL. A full list of sessions and abstracts at EASL relating to SuperSonic Imagine's ShearWave™ Elastography Technology is available at [www.easl.eu](http://www.easl.eu).

### SuperSonic Imagine

Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave™ Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer in the main global markets. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI.

For more information about SuperSonic Imagine, please go to [www.supersonicimagine.com](http://www.supersonicimagine.com).

### Contact information:

#### SuperSonic Imagine

Marketing & Communication  
Emmanuelle Vella  
[emmanuelle.vella@supersonicimagine.com](mailto:emmanuelle.vella@supersonicimagine.com)  
04 86 79 03 27

#### Blueprint Life Science Group

Investor Relations - US  
Candice Knoll  
[cknoll@bplifescience.com](mailto:cknoll@bplifescience.com)  
415 375 3340 Ext. 105



#### NewCap

Investor Relations - EU  
Pierre Laurent / Florent Alba  
[supersonicimagine@newcap.fr](mailto:supersonicimagine@newcap.fr)  
+33 1 44 71 98 55

#### ComCorp

Media Relations  
Florence Portejoie  
[fportejoie@comcorp.fr](mailto:fportejoie@comcorp.fr)  
+33 1 58 18 32 58 - +33 6 88 84 81 74  
Adelaïde Manester  
[amanester@comcorp.fr](mailto:amanester@comcorp.fr)  
+33 1 58 18 32 58 - +33 6 70 45 74 37

<sup>1</sup> Non-invasive marker of liver disease Management - Thursday April 23 - Strauss 1 -16:30 - 16:45  
Abstract O018: 2D-SHEAR WAVE ELASTOGRAPHY IS EQUIVALENT OR SUPERIOR TO TRANSIENT ELASTOGRAPHY FOR LIVER FIBROSIS ASSESSMENT: RESULTS FROM AN INDIVIDUAL PATIENT DATA BASED META-ANALYSIS

Eva Herrmann (Germany)

<sup>2</sup> Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Am J Gastroenterol. 2002 Oct;97(10):2614-8.

<sup>3</sup> Sampling variability of liver fibrosis in chronic hepatitis C. Bedossa P, Dargère D, Paradis V. Hepatology. 2003 Dec;38(6):1449-57.

<sup>4</sup> Sources of variability in histological scoring of chronic viral hepatitis. Rousselet MC, Michalak S, Dupré F, Croué A, Bedossa P, Saint-André JP, Calès P; Hepatitis Network 49. Hepatology. 2005 Feb;41(2):257-64.